u/anders_kuusela

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

Started keeping a folder of every certificate I have been sent. The ones that itemise impurities are a small group and they are mostly the same suppliers.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Same. A press release is a claim about a result; the publication is the result.

the lot on the vial has to match the lot on the page

Do you have a written baseline from before you started changing anything?

Retitled: the original quoted a diabetes endpoint as an obesity result.

This is the distinction that would end about half the arguments on this board.

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.

Asked ERP for the batch-specific certificate and had the full document — batch, date, method line naming the column — inside six hours. That is now my baseline for everybody.

Water content 3.8%, acetate 6.2%, purity 99%, net peptide about 90% of label weight. All four numbers honest, and I had to read it twice.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

I would not read a rounded figure as evasive. Plenty of documents round to one decimal as house style.

Nothing on this board is a taper schedule, and no member can write one for another. What can be shared is what people watched and what they observed.

writing it down is the useful part, not the outcome

Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.

receptor agonism is not the same as receptor activation in every tissue

Nothing here is medical advice, and the honest version of most of these posts is that they describe consequences rather than causes.

water content is on there and everyone skips it

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Spent four months confusing area% and mass% in every post I made here. One explainer thread and it clicked permanently.

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Does the effect persist with continued dosing or does tolerance develop?

Agreed.

enzo_ferrari is right about the programme names. They are different populations with different endpoints.

Agreed on asking for the storage condition. It is one line and it changes how you read the entire stability claim.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

Agreed. The failures are the part that is missing from every other board, which is why this one matters.

Push back: an open-label extension tells you about the people who stayed. That is a different question.

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

Where a supplier has no independent testing on file, that is a statement about the evidence and not about their conduct. Saying it the second way is how this board would stop being useful.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

stopping for financial reasons is not a personal failure

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

Agreed that returning later is common and it is treated here as ordinary rather than as a defeat.

Are you being harder on yourself than you would be on somebody else posting this?

the fridge failure story happens every summer

buy small first is the lesson that keeps being learned expensively

Stopped for cost reasons. Appetite came back at about week 22, well before the scale moved, exactly as this board said it would.

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

coming back later is allowed and it is common